These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7909313)

  • 1. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.
    Barker EL; Westphal RS; Schmidt D; Sanders-Bush E
    J Biol Chem; 1994 Apr; 269(16):11687-90. PubMed ID: 7909313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists.
    Westphal RS; Sanders-Bush E
    Mol Pharmacol; 1994 Nov; 46(5):937-42. PubMed ID: 7969083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
    Westphal RS; Sanders-Bush E
    Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mianserin-induced down-regulation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y.
    Newton RA; Elliott JM
    J Neurochem; 1997 Sep; 69(3):1031-8. PubMed ID: 9282925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional reconstitution in situ of 5-hydroxytryptamine2c (5HT2c) receptors with alphaq and inverse agonism of 5HT2c receptor antagonists.
    Hartman JL; Northup JK
    J Biol Chem; 1996 Sep; 271(37):22591-7. PubMed ID: 8798428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
    Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
    J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating mutations of the serotonin 5-HT2C receptor.
    Herrick-Davis K; Egan C; Teitler M
    J Neurochem; 1997 Sep; 69(3):1138-44. PubMed ID: 9282936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
    Barker EL; Sanders-Bush E
    Mol Pharmacol; 1993 Oct; 44(4):725-30. PubMed ID: 8232222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor.
    Herrick-Davis K; Grinde E; Gauthier C; Teitler M
    Ann N Y Acad Sci; 1998 Dec; 861():140-5. PubMed ID: 9928251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment.
    Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
    Eur J Pharmacol; 1994 Oct; 269(2):201-8. PubMed ID: 7851496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.
    Hietala J; Kuonnamäki M; Pälvimäki EP; Laakso A; Majasuo H; Syvälahti E
    Psychopharmacology (Berl); 2001 Sep; 157(2):180-7. PubMed ID: 11594443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus.
    Barker EL; Burris KD; Sanders-Bush E
    Brain Res; 1991 Jun; 552(2):330-2. PubMed ID: 1655172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.
    Fiorella D; Helsley S; Rabin RA; Winter JC
    Psychopharmacology (Berl); 1995 Dec; 122(3):237-43. PubMed ID: 8748393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.
    Leonhardt S; Gorospe E; Hoffman BJ; Teitler M
    Mol Pharmacol; 1992 Aug; 42(2):328-35. PubMed ID: 1355262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
    Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
    J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin agonists increase transferrin levels via activation of 5-HT1C receptors in choroid plexus epithelium.
    Esterle TM; Sanders-Bush E
    J Neurosci; 1992 Dec; 12(12):4775-82. PubMed ID: 1334504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells.
    Labrecque J; Fargin A; Bouvier M; Chidiac P; Dennis M
    Mol Pharmacol; 1995 Jul; 48(1):150-9. PubMed ID: 7623769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation.
    Pälvimäki EP; Majasuo H; Kuoppamäki M; Männistö PT; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1998 Mar; 136(2):99-104. PubMed ID: 9551765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.